Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide (original) (raw)

References

1. Anichini A, Fossati G, Parmiani G (1987) Clonal analysis of the cytolytic T-cell response to human tumors. Immunol Today 385
2. Anichini M, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M, Parmiani G (1993) Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 177: 989
   PubMed Google Scholar
3. Barth RJ, Mulé JJ, Spiess PJ, Rosenberg SA (1991) Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647
   PubMed Google Scholar
4. Boon T (1992) Toward a genetic analysis of tumor rejection antigens. In: Advances in cancer research. Academic Press, New York, p 177
   Google Scholar
5. Boon T (1993) Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54: 177
   PubMed Google Scholar
6. Brasseur F, Marchand M, Vanwijck R, Hérin M, Lethé B, Chomez P, Boon T (1992) Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 52: 839
   PubMed Google Scholar
7. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie PG, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanoma. J Exp Med 178: 489
   PubMed Google Scholar
8. Bystryn J-C (1993) Tumor vaccines. Cancer Metastasis Rev 9: 81
   Google Scholar
9. Carreno BM, Turner RV, Biddison WE, Coligan JE (1992) Overlapping epitopes that are recognized by CD8+ HLA class I-restricted and CD4+ class II-restricted cytotoxic T lymphocytes are contained within and influenza nucleoprotein peptide. J Immunol 148: 894
   PubMed Google Scholar
10. Cheever MA, Thompson DB, Klarnet JP, Greenberg PD (1986) Antigen-driven long-term cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy and persist long-term as functional memory T cells. J Exp Med 163: 1100
    PubMed Google Scholar
11. Chen BP, DeMars R, Sondel PM (1987) Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant epstein-barr virus-transformed lymphoblastoid cell lines. Hum Immunol 18: 75
    PubMed Google Scholar
12. Chestnut RW, Grey HM (1986) Antigen presentation by B cells and its significance in T-B interactions. Adv Immunol 39: 51
    PubMed Google Scholar
13. Coulie PG, Somville M, Lehmann F, Hainaut P, Brasseur F, Devos R, Boon T (1992) Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 50: 289
    PubMed Google Scholar
14. Darrow TL, Slingluff CL Jr, Seigler HF (1989) The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. J Immunol 142: 3329
    PubMed Google Scholar
15. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora J, Wolfel T, Sibille C, Chomez P, Boon T (1988) Immunogenic (tum−) variants of mouse tumor P815: cloning of the gene of tumantigen P91A and identification of the tum− mutation. Proc Natl Acad Sci USA 85: 2274
    PubMed Google Scholar
16. Elliott BE, Carlow DA, Rodricks A-M, Wade A (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181
    PubMed Google Scholar
17. Elliott T, Townsend A, Cerundolo V (1990) Naturally processed peptides. Nature 348: 195
    PubMed Google Scholar
18. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, Jongh BM de, Drijhout JW, Shegget J ter, Melief CJ, MKast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242
    PubMed Google Scholar
19. Hellström KE, Hellström I (1991) Principles of tumor immunity: tumor antigens. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, p 35
    Google Scholar
20. Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL (1993) Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunol Methods 13: 18
    Google Scholar
21. Hu S-L, Hellström I, Hellström KE (1992) Recent advances in antitumor vaccines. In: Ellis RW (ed). Vaccines: new approaches to immunological problems. Butterworth-Heinemann, Boston, p 327
    Google Scholar
22. Inaba K, Metlay JP, Crowley MT, Steinman RM (1990) Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ. J Exp Med 172: 631
    PubMed Google Scholar
23. Issekutz T, Chu E, Geha RS (1982) Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells. J Immunol 129: 1446
    PubMed Google Scholar
24. Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellström KE, Hellström I, Greenberg P (1991) CD4+ cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146: 3235
    PubMed Google Scholar
25. Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA (1992) Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 148: 638
    PubMed Google Scholar
26. Klarnet JP, Matis LA, Kern DE, Mizuno MT, Peace DJ, Thompson JA, Greenberg PD, Cheever MA (1987) Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated lenkemia and provide specific immunologic memory. J Immunol 138: 4012
    PubMed Google Scholar
27. Klein G, Sjögren HO, Klein E, Hellström KE (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 20: 1561
    PubMed Google Scholar
28. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora J, Janssens C, Reddehase M, Lejeune J, Boon T (1989) Structure of the gene coding for tum− transplantation antigen P91A. Cell 58: 293
    PubMed Google Scholar
29. Quentmeier H, Klaucke J, Mühlradt PF, Drexler HG (1992) Role of IL-6, IL-2, and IL-4 in the in vitro induction of cytotoxic T cells. J Immunol 149: 3316
    PubMed Google Scholar
30. Restifo NP (1992) Antigen processing and presentation: an update. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, p 1
    Google Scholar
31. Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA (1992) A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 175: 1423
    PubMed Google Scholar
32. Restifo NP, Esquivel F, Kawakami Y, Yewdell JM, Mulé JJ, Rosenberg SA, Bennick JR (1993) Identification of human cancers deficient in antigen processing. J Exp Med 177: 265
    PubMed Google Scholar
33. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257: 238
    PubMed Google Scholar
34. Rosenberg SA, Spiess PS, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318
    PubMed Google Scholar
35. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889
    PubMed Google Scholar
36. Rosenberg SA, Packard B, Aebersold P, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson, C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676
    PubMed Google Scholar
37. Schild H, Norda M, Deres K, Falk K, Rötzschke O, Wiesmüller K-H, Jung G, Rammensee H-G (1991) Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J Exp Med 174: 1665
    PubMed Google Scholar
38. Schreiber H, Ward PL, Rowley DA, Stauss HJ (1988) Unique tumor-specific antigens. Adv Cancer Res 6: 465
    Google Scholar
39. Schwartzentruber DJ, Topalian SL, Mancini M, Rosenberg SA (1991) Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-α, and IFN-gamma by human tumor infiltrating lymphocytes after autologous tumor stimulation. J Immunol 146: 3674
    PubMed Google Scholar
40. Sibille C, Chomez P, Wildmann C, Van Pel A, De Plaen E, Maryanski JL, Bergeyck V de, Boon T (1990) Structure of the gene of tum− transplantation antigen P198: a point mutation generates a new antigenic peptide. J Exp Med 173: 35
    Google Scholar
41. Skipper J, Stauss HJ (1993) Identification of two cytotoxic T lymphocytes-recognized epitopes in the ras protein. J Exp Med 177: 1493
    PubMed Google Scholar
42. Sporn JR, Ergin MT, Robbins GR, Cable RG, Silver H, Mukherji B (1993) Adoptive immunotherapy with peripheral blood lymphocytes cocultured in vitro with autologous tumor cells and interleukin-2. Cancer Immunol Immunother 37: 175
    PubMed Google Scholar
43. Tanaka K, Yoshioka T, Bieberich C, Jay G (1988) Role of the major histocompatability complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6: 359
    PubMed Google Scholar
44. Topalian SL, Muul LM, Solomon D, Rosenberg SA (1987) Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 102: 127
    PubMed Google Scholar
45. Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714
    PubMed Google Scholar
46. Townsend A, Bodmer H (1989) Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7: 601
    PubMed Google Scholar
47. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959
    PubMed Google Scholar
48. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plain E, Amar-Costesec A (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by CTL directed against tumor antigen MZ2-E. J Exp Med 176: 1453
    PubMed Google Scholar
49. Traversari C, Van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T (1992) Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35: 145
    PubMed Google Scholar
50. Utz U, Koenig S, Coligan JE, Biddison WE (1992) Presentation of three different viral peptides, HTLV-1 TAX, HCMV gB, and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. J Immunol 149: 214
    PubMed Google Scholar
51. Van den Eynde B, Lethé B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen to tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173: 1373
    PubMed Google Scholar
52. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van den Eynde B, Kunth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on human melanoma. Science 254: 1643
    PubMed Google Scholar
53. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg SA (1994) Expression of the MAGE-1 tumor antigen is upregulated by the demethylating agent 5 aza 2′ deoxycytidine. Cancer Res (in press)
54. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA (1993) A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53: 3257
    PubMed Google Scholar
55. Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL (1993) Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 150: 3101
    PubMed Google Scholar
56. Zakut R, Topalian SL, Kawakami Y, Mancini M, Eliyahu S, Rosenberg SA (1993) Differential expression of MAGE-1,-2,-3 messenger RNA in transformed and normal human cell lines. Cancer Res 53: 54
    Google Scholar

Download references